A Phase 2 interventional study of nilotinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Japan. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2024-08-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 9th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 2, and was the 14th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2013.
This study's enrollment of 15 is below the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 35 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 23rd largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2013, is one of 13 in phase 2, and was the 25th registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study and are benefiting from the treatment as judged by the investigator.
This was an open label, multi-center, phase II study to collect and assess long-term safety of nilotinib to patients treated in Novartis sponsored clinical studies (NCT00785785 and NCT00718562) and who were benefiting from treatment with nilotinib.
There was no screening period for this study. At the enrolment visit the patient was consented to the study and eligible patients started their treatment with nilotinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Drug: nilotinib
Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with adverse events (AEs) (any AE regardless of seriousness), serious adverse events (SAEs), Fatal SAEs and treatment related AEs.
Time frame: Adverse events were reported from enrolment until 30 days after last dose of study treatment, up to approximately 10.3 years.
Participants took part in 11 investigative sites in Japan.
| Milestone | Nilotinib |
|---|---|
| Started | 15 |
| Completed | 2 |
| Not completed | 13 |
| Withdrew: Disease progression | 9 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number of participants with adverse events (AEs) (any AE regardless of seriousness), serious adverse events (SAEs), Fatal SAEs and treatment related AEs.
| Participants | Nilotinib |
|---|---|
| Adverse Events | 13 |
| AEs-Treatment-related | 8 |
| Serious Adverse Events | 9 |
| SAEs-Treatment-related | 3 |
| Fatal SAEs | 1 |
| Fatal SAEs-Treatment-related | 0 |
Collected over Adverse events were reported from enrolment until 30 days after last dose of study treatment, up to approximately 10.3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | 1/15 (6.7%) | 9/15 (60%) | 12/15 (80%) |
| Event | Nilotinib |
|---|---|
| Acute myocardial infarctionCardiac disorders | 2/15 |
| CataractEye disorders | 1/15 |
| IleusGastrointestinal disorders | 1/15 |
| Small intestinal haemorrhageGastrointestinal disorders | 1/15 |
| DehydrationMetabolism and nutrition disorders | 1/15 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/15 |
| Cerebellar infarctionNervous system disorders | 1/15 |
| Cerebrovascular insufficiencyNervous system disorders | 1/15 |
| Thrombotic cerebral infarctionNervous system disorders | 1/15 |
| Event | Nilotinib |
|---|---|
| NasopharyngitisInfections and infestations | 5/15 |
| Oedema peripheralGeneral disorders | 4/15 |
| InfluenzaInfections and infestations | 3/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/15 |
| AnaemiaBlood and lymphatic system disorders | 2/15 |
| Dental cariesGastrointestinal disorders | 2/15 |
| MalaiseGeneral disorders | 2/15 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/15 |
| HypertensionVascular disorders | 2/15 |
| Angina pectorisCardiac disorders | 1/15 |
| Age, Continuous(years) | Nilotinib |
|---|---|
| Mean | 64.5 ± 13.39 |
| Sex: Female, Male(Participants) | Nilotinib |
|---|---|
| Female | 7 |
| Male | 8 |
| Race/Ethnicity, Customized(Participants) | Nilotinib |
|---|---|
| Japanese | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Jun 2013 to primary completion in Oct 2023, 123 months.
Results were first posted in Aug 2024, 10 months after primary completion.
Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's 123 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Gastrointestinal Stromal Tumors →